• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞色素P450 2D6B等位基因与阿尔茨海默病中较轻的突触病理学相关。

The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease.

作者信息

Chen X, Xia Y, Alford M, DeTeresa R, Hansen L, Klauber M R, Katzman R, Thal L, Masliah E, Saitoh T

机构信息

Department of Neurosciences, University of California at San Diego, La Jolla 92093-0624, USA.

出版信息

Ann Neurol. 1995 Oct;38(4):653-8. doi: 10.1002/ana.410380415.

DOI:10.1002/ana.410380415
PMID:7574463
Abstract

Both genetic and environmental factors affect the progression of Alzheimer's disease (AD). The presence of cortical Lewy bodies in AD patients is associated with an altered presentation of AD pathology suggestive of an interaction between the pathogenesis of Lewy bodies and AD lesions. Since the CYP2D6B mutant allele is often present in patients with Lewy body diseases (Parkinson's disease and Lewy body variant of AD), we extended these prior observations by studying the neuropathology associated with the presence of the CYP2D6B mutant allele in a pure AD population without Lewy bodies. AD patients who possessed the CYP2D6B mutant allele, in comparison with those without the CYP2D6B allele, were found to have a smaller decline in two synaptic markers, choline acetyltransferase and synaptophysin, in the frontal cortex relative to normal control values. On the other hand, senile plaques and neurofibrillary tangles were not significantly affected by the presence of the CYP2D6B mutant allele in the frontal cortex of AD patients. Association of the CYP2D6B mutant allele with Lewy body formation in both Parkinson's disease and the Lewy body variant of AD and with the milder synaptic pathology in pure AD without Lewy bodies suggest that depending on the contribution of other genetic and environmental factors, this mutant allele may be involved with different aspects of neurodegeneration.

摘要

遗传因素和环境因素都会影响阿尔茨海默病(AD)的进展。AD患者中皮质路易小体的存在与AD病理学表现的改变有关,这提示路易小体发病机制与AD病变之间存在相互作用。由于CYP2D6B突变等位基因常出现在路易体病(帕金森病和AD的路易体变异型)患者中,我们通过研究在无路易小体的单纯AD人群中与CYP2D6B突变等位基因存在相关的神经病理学,扩展了这些先前的观察结果。与没有CYP2D6B等位基因的AD患者相比,拥有CYP2D6B突变等位基因的AD患者额叶皮质中两种突触标记物——胆碱乙酰转移酶和突触素相对于正常对照值的下降幅度较小。另一方面,AD患者额叶皮质中CYP2D6B突变等位基因的存在对老年斑和神经原纤维缠结没有显著影响。CYP2D6B突变等位基因在帕金森病和AD的路易体变异型中与路易小体形成相关,在无路易小体的单纯AD中与较轻的突触病理学相关,这表明取决于其他遗传和环境因素的作用,该突变等位基因可能参与神经退行性变的不同方面。

相似文献

1
The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease.细胞色素P450 2D6B等位基因与阿尔茨海默病中较轻的突触病理学相关。
Ann Neurol. 1995 Oct;38(4):653-8. doi: 10.1002/ana.410380415.
2
The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease.
Ann Neurol. 1995 Jan;37(1):110-2. doi: 10.1002/ana.410370120.
3
Alzheimer's disease and Lewy body disease: a comparative clinicopathological study.阿尔茨海默病与路易体病:一项比较性临床病理研究。
Ann Neurol. 1994 Jan;35(1):81-8. doi: 10.1002/ana.410350113.
4
Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease.载脂蛋白E基因型对阿尔茨海默病和路易体痴呆型老年痴呆症的影响。对阿尔茨海默病病因学理论的意义。
Am J Pathol. 1994 Dec;145(6):1472-84.
5
Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease.遗传学证据表明路易体变异型确实是阿尔茨海默病的一种表型变异。
Brain Cogn. 1995 Aug;28(3):259-65. doi: 10.1006/brcg.1995.1256.
6
[Neuropathology of Alzheimer's disease and mild cognitive impairment].[阿尔茨海默病与轻度认知障碍的神经病理学]
Rev Neurol. 2003;37(2):155-63.
7
Association of the apolipoprotein E epsilon 4 allele with clinical subtypes of autopsy-confirmed Alzheimer's disease.载脂蛋白E ε4等位基因与经尸检确诊的阿尔茨海默病临床亚型的关联。
Am J Med Genet. 1994 Sep 15;54(3):199-205. doi: 10.1002/ajmg.1320540306.
8
A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease.一种现代假说:帕金森病与阿尔茨海默病相关痴呆的不同病理表现。
Dement Geriatr Cogn Disord. 2008;25(4):301-8. doi: 10.1159/000119104. Epub 2008 Mar 3.
9
Association between the oxidative polymorphism and early onset of Parkinson's disease.氧化多态性与帕金森病早发之间的关联。
Clin Pharmacol Ther. 1995 Mar;57(3):291-8. doi: 10.1016/0009-9236(95)90154-X.
10
Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.阿尔茨海默病的分子病理学与药物基因组学:多因素治疗对认知、焦虑和抑郁的多基因相关效应。
Methods Find Exp Clin Pharmacol. 2007 Jul;29 Suppl A:1-91.

引用本文的文献

1
Computational prognostic evaluation of Alzheimer's drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches.基于结构构象动力学和药物重定位方法,从 FDA 批准的数据库中计算预测阿尔茨海默病药物的疗效。
Sci Rep. 2023 Oct 21;13(1):18022. doi: 10.1038/s41598-023-45347-1.
2
The role of Beta-adrenergic receptor blockers in Alzheimer's disease: potential genetic and cellular signaling mechanisms.β-肾上腺素能受体阻滞剂在阿尔茨海默病中的作用:潜在的遗传和细胞信号转导机制。
Am J Alzheimers Dis Other Demen. 2013 Aug;28(5):427-39. doi: 10.1177/1533317513488924. Epub 2013 May 20.
3
Pharmacogenomics and therapeutic prospects in dementia.
痴呆症的药物基因组学与治疗前景
Eur Arch Psychiatry Clin Neurosci. 2008 Mar;258 Suppl 1:28-47. doi: 10.1007/s00406-007-1006-x.
4
Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.阿尔茨海默病治疗优化的药物遗传学基础。
Mol Diagn Ther. 2007;11(6):385-405. doi: 10.1007/BF03256262.
5
Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds.脑内细胞色素P450在临床药代动力学中的潜在作用:内源性化合物的调节作用
Clin Pharmacokinet. 2004;43(11):693-706. doi: 10.2165/00003088-200443110-00001.
6
Drug-metabolizing cytochrome P450s in the brain.大脑中的药物代谢细胞色素P450酶
J Psychiatry Neurosci. 2002 Nov;27(6):406-15.
7
Epidemiology of the dementias: recent developments and new approaches.痴呆症的流行病学:最新进展与新方法
J Neurol Neurosurg Psychiatry. 1996 May;60(5):478-88. doi: 10.1136/jnnp.60.5.478.